Ginkgo biloba in the management of the COVID-19 severity.
Arch Pharm (Weinheim)
; 355(10): e2200188, 2022 Oct.
Статья
в английский
| MEDLINE | ID: covidwho-1877557
ABSTRACT
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is linked with inflammatory disorders and the development of oxidative stress in extreme cases. Therefore, anti-inflammatory and antioxidant drugs may alleviate these complications. Ginkgo biloba L. folium extract (EGb) is a herbal medicine containing various active constituents. This review aims to provide a critical discussion on the potential role of EGb in the management of coronavirus disease 2019 (COVID-19). The antiviral effect of EGb is mediated by different mechanisms, including blocking SARS-CoV-2 3-chymotrypsin-like protease that provides trans-variant effectiveness. Moreover, EGb impedes the development of pulmonary inflammatory disorders through the diminution of neutrophil elastase activity, the release of proinflammatory cytokines, platelet aggregation, and thrombosis. Thus, EGb can attenuate the acute lung injury and acute respiratory distress syndrome in COVID-19. In conclusion, EGb offers the potential of being used as adjuvant antiviral and symptomatic therapy. Nanosystems enabling targeted delivery, personalization, and booster of effects provide the opportunity for the use of EGb in modern phytotherapy.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Ginkgo biloba
/
COVID-19 Drug Treatment
Тип исследования:
Прогностическое исследование
Темы:
Традиционная медицина
/
Вакцина
/
Варианты
Пределы темы:
Люди
Язык:
английский
Журнал:
Arch Pharm (Weinheim)
Год:
2022
Тип:
Статья
Аффилированная страна:
Ardp.202200188
Документы, близкие по теме
MEDLINE
...
LILACS
LIS